On Nov. 1, BioMarin Pharmaceutical (NASDAQ:BMRN) released third-quarter earnings for the period ended Sept. 30.
- Revenues beat the estimates by 11.2%, while EPS topped the consensus estimate with a loss of $0.08.
- Revenue increases were mainly due to stronger product sales, particularly in Aldurazyme and Naglazyme.
- Restrained spending and top-line growth let to a significant movement toward profitability.
- Get our full Foolish Take on BioMarin's latest quarter.
(Figures in thousands, except per-share data)
Income Statement Highlights
|
Avg. Est. |
Q3 2006 |
Q3 2005 |
Change | |
|---|---|---|---|---|
|
Sales |
$19,716 |
$24,927 |
$7,579 |
228.9% |
|
Net Profit* |
-- |
($7,036) |
($15,476) |
N/A |
|
EPS |
($0.12) |
($0.08) |
($0.21) |
N/A |
|
Diluted Shares |
-- |
86,269 |
71,996 |
19.8% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q3 2006 |
Q3 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
89.52% |
97.84% |
(8.32) |
|
Operating Margin |
(16.51%) |
(173.82%) |
157.31 |
|
Net Margin |
(28.23%) |
(204.20%) |
175.97 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$293.9 |
$65.9 |
346% |
|
Accounts Rec. |
$13.0 |
$5.3 |
145.3% |
|
Inventory |
$25.8 |
$7.7 |
235.1% |
|
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Accounts Payable* |
$29.2 |
$22.9 |
27.5% |
|
Long-Term Debt |
$293.1 |
$214.4 |
36.7% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided.
Find out why Fools always follow the money.
Related Companies:
- Medarex (NASDAQ:MEDX)
- Crucell NV (NASDAQ:CRXL)
- Regeneron Pharmaceuticals (NASDAQ:REGN)
- ZymoGenetics (NASDAQ:ZGEN)
Related Foolishness:
Get the latest updates from the fast-paced world of biotech, and other spawning grounds for amazing growth stocks, with a free 30-day trial to Motley Fool Rule Breakers.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
